Saurabh Saha Sells 55,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $12.63, for a total value of $694,650.00. Following the transaction, the chief executive officer now owns 221,017 shares of the company’s stock, valued at approximately $2,791,444.71. The trade was a 19.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, May 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.71, for a total value of $699,050.00.
• On Monday, April 21st, Saurabh Saha sold 14,656 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.29, for a total value of $180,122.24.

Centessa Pharmaceuticals Trading Down 2.0%

Shares of CNTA stock opened at $12.43 on Friday. The stock has a market capitalization of $1.66 billion, a PE ratio of -6.87 and a beta of 1.48. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $8.46 and a 1-year high of $19.09. The business has a 50-day moving average of $12.70 and a 200 day moving average of $14.85. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.15. As a group, sell-side analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently bought and sold shares of CNTA. JPMorgan Chase & Co. boosted its holdings in Centessa Pharmaceuticals by 40.1% during the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company’s stock valued at $3,189,000 after acquiring an additional 54,482 shares during the period. Wellington Management Group LLP lifted its holdings in Centessa Pharmaceuticals by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock worth $1,928,000 after buying an additional 14,494 shares during the period. Franklin Resources Inc. lifted its holdings in Centessa Pharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock worth $38,668,000 after buying an additional 6,000 shares during the period. Geode Capital Management LLC lifted its holdings in Centessa Pharmaceuticals by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after buying an additional 660 shares during the period. Finally, Trexquant Investment LP lifted its holdings in Centessa Pharmaceuticals by 52.8% in the 4th quarter. Trexquant Investment LP now owns 261,184 shares of the company’s stock worth $4,375,000 after buying an additional 90,233 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Chardan Capital assumed coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set a “buy” rating and a $30.00 target price for the company. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a “buy” rating and a $35.00 price objective for the company. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an “overweight” rating and a $38.00 price objective for the company. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.89.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.